March 2017
 
Table of Contents
 


Funding Opportunities

 

View a full list of current funding opportunities. 




Open
Recruitments
Highlighted positions related to cancer for which VCU is currently hiring. View the full list.

 

Associate Director, Basic Research (F51620) 

 

Program Co-Leader, Cancer Molecular Genetics (F36090)





Shared Resource Spotlight
Cancer Informatics Core

The Cancer Informatics Core facilitates biomedical and translational research by providing methods and tools to record, integrate, manage, analyze and visualize various biomedical, behavioral and clinical data. Available services include consultation, data integration and honest broker services, feasibility assessment, cohort identification, clinical annotation, dataset and report development, electronic data capture and bioinformatics support. These services rely on the CIC Universal Data Store, which consists of consolidated and linked data from VCU Health System's various clinical-related data systems. 

 

To request a CIC service, except for Bioinformatics, fill out a CIC Service Request Form.

 

To request Bioinformatics services, fill out a Massey Bioinformatics Service Request Form.

 

For more information, contact core director, Tamas Gal, Ph.D., at (804) 628-2123 or tsgal@vcu.edu.


Leaders' Update Update 
 
A message from Director Gordon Ginder

Dear colleagues,

 

I am delighted to share that in February the National Cancer Advisory Board affirmed the NCI review panel's evaluation of Massey. We are anticipating an official award notice for renewal of our NCI-designating Cancer Center Support Grant in May of this year.

 

This message continues with more on:

-the Scientific External Advisory Board's recent meeting at Massey

-change in Cancer Cell Signaling program leadership

-strategic recruitments underway

 

Research HighlightsHighlights
Research supports paradigm shift for the treatment of early stage pancreatic cancer
 
Emma Fields, M.D. Developmental Therapeutics research member
Massey research led by Emma Fields, M.D., suggests that adjuvant treatment is ineffective in treating early stage pancreatic cancer and supports an ongoing shift to the use of neoadjuvant chemoradiation to increase the chances for a more effective surgery, and enhance overall survival, tolerability and quality of life for patients.

 

Center News Center1
Massey expands its colorectal cancer team, preventative services and treatment options

The colorectal cancer team at Massey has expanded with the addition of two new colorectal surgeons, Jaime Bohl, M.D., and Emily Rivet, M.D. They provide colonoscopies and surgical care for colorectal cancer. In addition to seeing patients on the MCV campus, they operate a clinic at an all new Stony Point building. Also new to Massey is a complex treatment for advanced colorectal cancer and other abdominal cancers offered by Leopoldo Fernandez, M.D., known as HIPEC (heated intraperitoneal chemotherapy). In this procedure, a heated chemotherapy solution is circulated throughout the abdominal cavity to kill any remaining cells following surgery.

Member Showcase MemberShowcase

Chalfant named program leader of Cancer Cell Signaling


Chalfant
Cancer Cell Signaling co-leader
Charles Chalfant has been appointed as the co-leader of the Cancer Cell Signaling research program at Massey. He will serve in this capacity alongside Andrew Larner, who has also co-led the program since its inception in 2011. As co-leader, Chalfant will help develop and guide the strategic direction of the CCS program, focusing on opportunities to grow its membership, foster transdisciplinary collaboration among its members, increase its cancer-focused grant funding and facilitate translational research.


Researcher Recognition Recognition
Manjili's study most read article over the last six months in JLB

Cancer Cell Signaling member
A study led by Masoud Manjili, D.V.M., Ph.D., was identified as the most read publication in the
Journal of Leukocyte Biology over the last six months. Manjili developed a chemo-immunotherapeutic protocol that overcame tumor-induced suppression, heightened tumor cells' vulnerability to immunotherapy and extended survival in mouse models of metastatic breast cancer. The findings suggest that the administration of immunotherapy following the completion of chemotherapy, and during tumor dormancy, could help prevent deaths caused by the recurrence of metastatic breast cancer.


EventsUpcoming Events

Cancer Research Seminars
Ukrop's Monument Avenue 10k
Massey is the official charitable partner of the Ukrop's Monument Avenue 10k presented by Kroger on Saturday, April 1st. Team Massey has more than 30 teams signed up with a goal of raising $500,000. Consider accepting the Massey Challenge and joining us as we put cancer on the run!


For a full listing of events, 

mediaMassey in the Media
 

NewsTop Cancer News
  
JNCI
Share with us your research, awards and accomplishments!
Submit your news to Blake Belden at beldenba@vcu.edu or (804) 628-4578.
  Connect with us!
Join Massey's online communities.
Like us on Facebook
Follow us on Twitter
View our videos on YouTube